Michel Druet-Cabanac

Michel Druet-Cabanac

Auto-generated profile, based on publicly available information

Michel Druet-Cabanac

INSERM UMR1094 Tropical Neuroepidemiology Limoges France

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in The Lancet Neurology
Verified
Journal Article
Closed access
PPPierre-Marie Preux
Pierre-Marie Preux
MDMichel Druet-Cabanac
Michel Druet-Cabanac

1 October 2014 in The Lancet Neurology
Verified
Journal Article
Closed access
ABAwa Ba-Diop
Awa Ba-Diop
BMBenoît Marin
Benoît Marin
MDMichel Druet-Cabanac
Michel Druet-Cabanac
ENEdgard B Ngoungou
Edgard B Ngoungou
CNCharles Newton
Charles Newton
PPPierre-Marie Preux
Pierre-Marie Preux

31 May 2011 in Epilepsia
Verified
Journal Article
Open access
PDF file
LYLuce‐Perrine Yemadje
Luce‐Perrine Yemadje
DHDismand Houinato
Dismand Houinato
FQFabrice Quet
Fabrice Quet
MDMichel Druet‐Cabanac
Michel Druet‐Cabanac
PPPierre‐Marie Preux
Pierre‐Marie Preux
Summary: Epilepsy is a frequent chronic neurologic disorder that affects nearly 70 million people worldwide. The majority of people with epilepsy live in developing countries, where epilepsy remains a major public health problem. Wide prevalence differences exist among various populations across sub‐Saharan Africa, Latin America, and Asia. In particular, prevalence is lower in Southeast Asia than in sub‐Saharan Africa and Latin America. Methodologic problems alone do not seem to explain these differences shown in recent review papers. The distribution of numerous risk or etiologic factors such as infectious diseases with neurologic sequel, head injuries, or genetic factors could explain these differences. Stigmatization of people with epilepsy could lead to underestimating the prevalence of epilepsy, even in well‐conducted studies. It is important to standardize the process of epidemiologic monitoring of epilepsy in order to improve the reliability in data comparison. Understanding the reasons for these differences is a crucial issue for eventually raising new hypotheses or prevention strategies.

19 June 2003 in Epilepsia
Verified
Journal Article
Open access
PDF file
GNGeorges Nsengiyumva
Georges Nsengiyumva
MDMichel Druet‐Cabanac
Michel Druet‐Cabanac
BRBienvenue Ramanankandrasana
Bienvenue Ramanankandrasana
BBBernard Bouteille
Bernard Bouteille
LNLéopold Nsizabira
Léopold Nsizabira
PPPierre‐Marie Preux
Pierre‐Marie Preux
Summary:  Purpose: Human cysticercosis is a direct consequence of infection by Taenia solium larvae (Cysticercus cellulosae). Results of studies on the impact of neurocysticercosis on epilepsy in Africa are inconsistent. The objective was to evaluate the role of cysticercosis in epilepsy in Burundi. Methods: A prevalent matched case–control design was used in the Kiremba area, Burundi, between March and April 2001. One case with epilepsy was matched to two control subjects, according to their age. Cases were subjects who had shown at least two unprovoked epileptic seizures within a 24‐h time range and who lived in the Kiremba area. The control subjects also lived in Kiremba and had neither neurologic illness nor kinship with the people with epilepsy. Seropositivity for cysticercosis was the exposure variable. Three hundred twenty‐four prevalent cases, with onset of epilepsy between 1950 and 2000, and 648 age‐matched controls were included. Results: This study found a link between cysticercosis infestation and the occurrence of epilepsy (odds ratio, 3.8; 95% confidence interval, 2.5–5.1). Conclusions: The study highlighted the importance of cysticercosis in the area of Kiremba, as 31.5% of the control subjects screened positive for this parasite. The attributable risk for cysticercosis was 50% (95% confidence interval, 42–57) in this population.

1 June 2011 in Expert Review of Neurotherapeutics
Verified
Journal Article
Closed access
DBDevender Bhalla
Devender Bhalla
BGBertrand Godet
Bertrand Godet
MDMichel Druet-Cabanac
Michel Druet-Cabanac
PPPierre-Marie Preux
Pierre-Marie Preux
Epilepsy is a heterogeneous disorder, the symptoms of which are preventable and controllable to some extent. Significant inter- and intra-country differences in incidence and prevalence exist because multiple etiologic factors are implicated. Many past reviews have addressed sole etiologies. We considered a comprehensive view of all etiologies (genetic/structural/metabolic) to be significant for both the developing and the developed world as well as routine clinical/epidemiology practice. We therefore carried out a comprehensive search for peer-reviewed articles (irrespective of year, region and language; chosen based on novelty and importance) for each etiology. This article was felt to be essential since newer etiologic knowledge has emerged in recent years. Many new genetic links for rarer epilepsy forms have emerged. Epilepsy risk in limbic encephalitis, mechanisms of Alzheimer's-related epilepsy and the genetic basis of cortical malformations have been detailed. An etiological approach to epilepsy in combination with the conventional classification of epilepsy syndromes is required to gain knowledge.

11 March 2008 in Neuroepidemiology
Verified
Journal Article
Closed access
MVM.C. Vázquez
M.C. Vázquez
CKC. Ketzoián
C. Ketzoián
CLC. Legnani
C. Legnani
IRI. Rega
I. Rega
NSN. Sánchez
N. Sánchez
MMM. Medici
M. Medici
Objective: To determine the incidence and prevalence of amyotrophic lateral sclerosis (ALS) in the Republic of Uruguay.Methods: The study was performed in Uruguay (3,241,003 inhabitants) during a 2-year period (2002–2003). To ensure complete case ascertainment, multiple sources of information were used, including all the neurologists, other medical specialties, general physicians, neurophysiology laboratories, hospital medical records and death certificates. ALS diagnosis was based on El Escorial criteria. Although all patients with motor neuron disease were enrolled in the follow-up, only probable and definite cases are included in the study. Results: Between January 1st, 2002, and December 31st, 2003, 89 new patients were diagnosed with probable or definite ALS. The mean annual incidence rate was 1.37 per 100,000 persons. The incidence was higher for men (1.95) than for women (0.84) with a male to female ratio of 2:1. For both, the incidence increased throughout the years showing a peak in the 65–74 age group among men and the 55–64 age group among women. Mean age at onset of ALS disease was 58.7 years. The estimated mean annual incidence for ALS calculated by the capture recapture method was 1.42 (95% CI, 1.13–1.72). On December 31st, 2002, the crude prevalence was 1.9 per 100,000 inhabitants. Conclusions: ALS incidence is within a narrow range across countries despite the genetic, environmental and socioeconomic differences when similar prospective design, diagnosis criteria and data analyses are applied.